Jim Lefevere
Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer
The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Patients are telling the truth — just not to you
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
Pharma-Exclusive Webinar: Redefining Engagement in the AI Era
Join Impetus Digital's pharma-exclusive webinar to discover how compliant AI tools and virtual workflows can elevate static programs into high-retention, interactive experiences without enterprise overhead.
Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn
The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases
Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments
MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain
NEW PHARMA-EXCLUSIVE WEBINAR: Beyond the Hype; Practical, Compliant AI Solutions for Pharma Engagement
See how top-tier pharma teams use compliant AI tools and virtual QIPs to capture real-time market intelligence, confidence scores, and audience insights from live dashboards
Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients
True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer
Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years
New benchmark reveals significant digital maturity gap across UK POM companies’ product-information estates
A new benchmark maps 100 UK prescription medicine companies across five maturity bands and finds a market at very different stages of digital development
Roche and Nurix Therapeutics to partner in $2.3bn deal
The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology